Raleigh specialty pharmaceutical company Dara Biosciences Inc (NASDAQ:DARA) filed notice to sell additional shares, with a proposed maximum sale of $32.5 million. DARA Biosciences Inc (NASDAQ:DARA) shares after opening at $2.57 moved to $2.57 on last trade day and at the end of the day closed at $2.13. Company price to sales ratio in past twelve months was calculated as 44.68 and price to cash ratio as 5.26. DARA Biosciences Inc (NASDAQ:DARA) showed a negative weekly performance of -20.52%.
Ovascience Inc (NASDAQ:OVAS) had its price target increased by Leerink Swann to $16.00 in a research report sent to investors on Thursday morning, Analyst Ratings News reports. OvaScience Inc (NASDAQ:OVAS) shares advanced 0.90% in last trading session and ended the day on $7.85. OVAS return on equity ratio is recorded as -57.00% and its return on assets is -53.90%. OvaScience Inc (NASDAQ:OVAS) yearly performance is -19.49%.
The Compensation Committee of Oragenics, Inc (NYSEMKT:OGEN) approved the 2014 performance objectives for the Company’s President and Chief Executive Officer, Dr. John Bonfiglio under his cash bonus plan. Oragenics Inc (NYSEMKT:OGEN) shares moved down -6.33% in last trading session and was closed at $2.22 while trading in range of $2.15 – $2.39 – Oragenics Inc (NYSEMKT:OGEN) year to date (YTD) performance is -21.00%.
Egalet Corporation (NASDAQ:EGLT)’s Bob Radie, president and chief executive officer presented the 13th Annual Needham Healthcare Conference on Wednesday. The conference will be held at the Westin NY Grand Central Hotel. Egalet Corp (NASDAQ:EGLT) weekly performance is -4.80%. On last trading day company shares ended up $10.72. Egalet Corp (NASDAQ:EGLT) distance from 50-day simple moving average (SMA50) is -22.57%. Analysts mean target price for the company is $19.67.